GSDME and melanoma: BRAFi + MEKi, which are FDA-approved for the treatment of BRAFV600E/K-mutant melanoma, activated DCs and tumor-specific T cells in melanoma by triggering GSDME-executed pyroptosis and promoting DAMP release (132).